Daklinza® is your ally in achieving high cure rates across Multiple Genotypes including advanced cirrhotic, PI-failure, HIV co-infected and post-liver-transplant HCV patients1,2,3,4,5

References

  1. Daklinza® Summary of Product Characteristics.
  2. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med. 2014;370:211-221.
  3. Adapted from Wyles et al. N Engl J Med. 2015. DOI:10.1056/NEJMoa1503153.
  4. Adapted from EASL Recommendations 2015, DOI:http:/dx.doi.org/10.1016/j.jhep. 2015.03.025. Accessed April 2015.
  5. Lacombe K et al. IAS 2015. Oral TUAB0207.